Analyst Consensus ?
ConsensusBuy25 ratings
Bullish2184.0%
Neutral416.0%
Bearish00.0%
Bunge Global S.A. · BG · FY2026 Q1 · Calendar Q2 2026
Bunge Beats Q1 Estimates, Raises Full-Year EPS Guidance on Viterra Synergies and Biofuels Demand
Bunge's first quarter of fiscal 2026 delivered a dramatic earnings beat, with adjusted EPS of $1.83 more than doubling the $0.88 consensus estimate. Management raised full-year adjusted EPS guidance from $7.50-$8.00 to $9.00-$9.50, driven by Viterra integration synergies, robust biofuels demand supported by EPA RVO policy, and expanded soybean and softseed processing capacity. Revenue of $21.86B came in below the $23.38B consensus, as tropical oils and grain merchandising segments faced market and freight headwinds. Despite the beat and raised outlook, the stock declined on the report, underperforming SPY by approximately 240 basis points, and has continued to drift lower. At $105.07, the shares trade at a meaningful discount to the $137 consensus price target, suggesting the market is pricing in sustainability concerns around the guidance increase or near-term margin pressures from…
Reported Before market openNYSEConsumer Defensive
$20.91B market cap
90quality score
Company context
Snapshot as of publicationBunge Global S.A., established in 1818 and headquartered in St. Louis, Missouri, operates as a prominent international agribusiness and food corporation. Its diverse operations are categorized into four main divisions: Agribusiness, Refined and Specialty Oils, Milling, and Sugar and Bioenergy. The Agribusiness segment involves the sourcing, storage, transportation, processing, and sale of agricultural goods and their derivatives. Key commodities include various oilseeds such as soybeans, rapeseed, canola, and sunflower seeds, alongside grains like wheat and corn. These oilseeds are further processed into vegetable oils and protein-rich meals. This segment supplies a wide range of clients, including animal feed and livestock producers, millers of wheat and corn, other oilseed processors, and companies involved in edible oil and biofuel production, catering to both industrial and biodiesel applications.…
Earnings scorecard
Reported versus consensus
Reported EPS
$1.83
Consensus $1
EPS surprise
+107.2%
Reported versus consensus
Reported revenue
$21.86B
Consensus $23.38B
Revenue surprise
-6.5%
Reported versus consensus
Earnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$105.88Current
$90Low
$121.55Average
$150High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Jul 31, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Barclays | Overweight | Overweight | Maintain | Apr 30, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Mar 24, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Mar 11, 2026 |
| BMO Capital | Outperform | Outperform | Maintain | Mar 11, 2026 |
| UBS | Buy | Buy | Maintain | Feb 5, 2026 |
| B of A Securities | Buy | Buy | Maintain | Dec 2, 2025 |
| Stephens & Co. | Overweight | Overweight | Maintain | Oct 17, 2025 |
| Citigroup | Neutral | Neutral | Maintain | Apr 15, 2025 |
| Goldman Sachs | Buy | Buy | Maintain | Feb 13, 2024 |
| HSBC | Buy | Hold | Upgrade | Feb 9, 2024 |
| Roth MKM | Buy | Buy | Maintain | Feb 5, 2024 |
| Baird | Neutral | Neutral | Maintain | Jan 23, 2024 |
| Wolfe Research | Peer Perform | Outperform | Downgrade | Jan 10, 2024 |
| Credit Suisse | Outperform | Outperform | Maintain | Jun 23, 2022 |
| Bank of America | Buy | Neutral | Upgrade | Aug 2, 2016 |
| BB&T Capital | Buy | Buy | Maintain | Jul 12, 2016 |
| Macquarie | Outperform | Outperform | Maintain | Oct 29, 2015 |
| Vertical Research | Buy | Buy | Maintain | Jul 7, 2015 |
| Feltl & Co. | Buy | Hold | Upgrade | Oct 23, 2013 |
| Miller Tabak | Hold | Buy | Downgrade | Oct 21, 2013 |
| PiperJaffray | Overweight | Neutral | Upgrade | Jun 12, 2013 |
| Piper Sandler | Overweight | Neutral | Upgrade | Jun 11, 2013 |
| Topeka | Buy | Hold | Upgrade | Jul 30, 2012 |
| Topeka Capital | Buy | Hold | Upgrade | Jul 29, 2012 |
| Scotiabank | Sector Outperform | Sector Outperform | Maintain | Apr 29, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $105.88. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Barclays | Analyst unavailable | $150 | $126.31 | +41.7% | Apr 30, 2026 |
| Morgan Stanley | Steven Haynes | $130 | $112.75 | +22.8% | Mar 5, 2026 |
| UBS | Analyst unavailable | $145 | $117.23 | +36.9% | Feb 5, 2026 |
| BMO Capital | Analyst unavailable | $130 | $117.23 | +22.8% | Feb 5, 2026 |
| Stephens | Analyst unavailable | $130 | $117.23 | +22.8% | Feb 5, 2026 |
| Coker Palmer | Thomas Palmer | $117 | $110.06 | +10.5% | Jan 21, 2026 |
| Morgan Stanley | Analyst unavailable | $95 | $97.6 | -10.3% | Oct 27, 2025 |
| Barclays | Benjamin Theurer | $105 | $97.25 | -0.8% | Oct 21, 2025 |
| Stephens | Analyst unavailable | $115 | $95.33 | +8.6% | Oct 17, 2025 |
| BMO Capital | Analyst unavailable | $110 | $93.09 | +3.9% | Oct 16, 2025 |
| Morgan Stanley | Steven Haynes | $83 | $83.14 | -21.6% | Aug 12, 2025 |
| CFRA | Arun Sundaram | $90 | $85.86 | -15.0% | Oct 30, 2024 |
| HSBC | Wesley Brooks | $105 | $104.06 | -0.8% | Apr 25, 2024 |
| Coker Palmer | Thomas Palmer | $122 | $105.79 | +15.2% | Apr 24, 2024 |
| UBS | Analyst unavailable | $133 | $94.47 | +25.6% | Dec 14, 2022 |
| Morgan Stanley | Analyst unavailable | $120 | $115.76 | +13.3% | May 2, 2022 |
| Credit Suisse | Analyst unavailable | $140 | $116.4 | +32.2% | Apr 28, 2022 |
| BMO Capital | Analyst unavailable | $144 | $118.96 | +36.0% | Apr 28, 2022 |
| Barclays | Analyst unavailable | $135 | $115.56 | +27.5% | Apr 25, 2022 |
Track every rating change on BG the moment it posts. Free to start.
Start freeMarket reaction
prior-close to event-session close
Stock move
-0.0%
Event window
SPY move
-0.0%
Same window
Abnormal move
-0.0%
Stock minus SPY
Volume
1.7×
Versus trailing sessions
Subsequent drift
-2.1%
Up to 20 sessions
BGSPY benchmark
Follow BG with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeTranscript intelligence
What changed
Q1 adjusted EPS of $1.83 vs $0.883 estimate, a 107.25% surprise. Revenue of $21.86B vs $23.38B estimate, a 6.50% miss. Full-year adjusted EPS guidance raised to $9.00-$9.50 from $7.50-$8.00. Viterra integration delivering synergies and an expanded global origination and logistics footprint. IFF soy protein concentrate and processing business acquired, expanding protein and lecithin portfolio. Readily marketable inventories now exceed net debt by approximately $400 million, reflecting strong liquidity. Stock underperformed SPY by ~240 bps on the report with continued downward drift since.
Guidance delta
Full-year adjusted EPS guidance was raised from $7.50-$8.00 to $9.00-$9.50, reflecting confidence in Viterra synergies, biofuels demand from EPA RVO policy, and expanded processing capacity. However, management forecast tropical oils and grain merchandising segments lower due to market conditions and elevated freight costs, introducing some caution about second-half margin sustainability.
Key takeaways
- Q1 adjusted EPS of $1.83 surpassed prior expectations by a wide margin.
- Full-year adjusted EPS guidance raised to $9.00-$9.50 from $7.50-$8.00.
- Viterra integration and IFF acquisition are driving diversification and cost synergies.
- Biofuels demand remains strong, buoyed by EPA RVO policy and higher crude and diesel prices.
- Tropical oils and grain merchandising segments are forecast lower due to market and freight headwinds.
Management priorities
- Complete integration of Viterra and capture remaining synergies.
- Expand biofuel production to meet growing RVO volumes.
- Invest in growth-related capital projects, including protein and lecithin capabilities.
- Pursue potential further share buybacks up to $250 million pending cash generation and leverage limits.
- Monitor crop planting shifts, El Nino effects, and global fertilizer dynamics.
- Leverage global logistics network to optimize origination, processing, and distribution.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-07-30T23:02:05.746568+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-30T23:02:05.743716+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.